Présentation de l'entreprise
Arcturus Therapeutics Holdings Inc. operates within the healthcare sector as a specialized entity in the biotechnology industry, focusing on the development of therapeutic solutions for rare diseases affecting the liver and respiratory systems. The company's operational scope is anchored in advanced technology platforms, specifically the STARR self-amplifying mRNA technology platform and the LUNAR lipid-mediated delivery system, which are central to its drug development pipeline. This biotechnology firm employs a workforce of 106 individuals and holds a market capitalization of $241.60M, reflecting its position as a mid-sized capitalization entity within the broader healthcare landscape. The annual revenue reported over the trailing twelve months stands at $82.03M, which, when combined with the current market cap, indicates that the company possesses a valuation multiple relative to its sales that suggests significant investor expectations regarding future product launches and commercialization potential despite its current size.
Santé financière
The financial performance of Arcturus Therapeutics Holdings Inc. over the trailing twelve months is characterized by a revenue of $82.03M paired with a net income of -$65,783,000 and an EBITDA of -$73,235,000, highlighting a substantial gap between top-line generation and bottom-line profitability that points to heavy operational costs typical of early-stage biotechnology development. Notably, the company generated free cash flow of $9.18M, a positive figure that provides essential financial flexibility to fund ongoing research and development activities without immediate reliance on external equity financing. The margin profile reveals significant operational challenges, with a gross margin of -36.8%, an operating margin of -435.1%, and a profit margin of -80.2%, indicating that current costs of goods sold and operating expenses are exceeding revenue generation across all levels of the business. Regarding liquidity and solvency, the company holds $230.91M in cash against $25.00M in debt, resulting in a debt-to-equity ratio of 11.68, which presents a complex balance sheet scenario where high leverage exists but is offset by a robust cash position. The current ratio of 6.64 further demonstrates strong short-term liquidity, suggesting the company has ample resources to cover its current liabilities without distress. Finally, the return on equity stands at -28.9% and the return on assets at -15.5%, metrics that reveal that management has not yet achieved profitability, as the company is currently destroying shareholder value in accounting terms due to the lack of net income relative to the equity base and asset base.
Évaluation de la valorisation
Valuation metrics for Arcturus Therapeutics Holdings Inc. present a distinct picture due to the absence of positive earnings, with a trailing P/E ratio of N/A and a forward P/E of -2.02, implying that the market is not pricing the stock based on current earnings but rather on future expectations of profitability that have not yet materialized. The price-to-book ratio is recorded at 1.13, indicating that the market values the company at a slight premium over its net asset book value, which is a relatively modest multiple for a biotechnology firm with significant intangible assets and development pipelines. Alternative valuation measures such as a price-to-sales ratio of 2.95 and an EV/EBITDA of -0.49 suggest that investors are willing to pay nearly three times current sales, a figure that must be scrutinized given the negative EBITDA and the speculative nature of the business model. The stock has traded between a 52-week low of $5.85 and a 52-week high of $24.17, and without the specific current share price provided in the facts, the position relative to this range remains undefined by the available data, though the wide beta of 2.44 indicates high volatility. This beta value signifies that the stock's price fluctuations are significantly amplified relative to the broader market, moving with greater intensity than the standard index.
Growth & Income
The growth profile of the company is defined by a year-over-year revenue decline of -68.4%, while earnings growth is listed as N/A, reflecting the company's current inability to generate positive net income and thus rendering growth rate comparisons on an earnings basis inapplicable. As the company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it follows a capital allocation strategy where earnings are theoretically reinvested into growth initiatives rather than distributed to shareholders, although the negative earnings make traditional reinvestment of profits impossible. The overall growth and income profile is therefore characterized by a contraction in top-line sales and a complete absence of dividend income, placing the company in a category of high-risk, high-volatility assets where capital appreciation relies entirely on the successful commercialization of its mRNA therapeutics for rare liver and respiratory diseases.